What I mean is that renal, although lower revenue, would have a very high margin because there would not be all the carry-on trying to get the hospitals etc testing to the protocol in lymphedema, liaising with private payors , trying to standardise policies - that will really cut into the bottom-line in the first couple of years.
Ann: Market Update - Executing Towards Profitability in Oncology, page-102
-
- There are more pages in this discussion • 16 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IPD (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
5.0¢ |
Change
-0.002(3.85%) |
Mkt cap ! $99.13M | |||
| Open | High | Low | Value | Volume |
| 5.2¢ | 5.3¢ | 4.9¢ | $87.17K | 1.746M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 434788 | 5.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 5.2¢ | 161029 | 5 |
View Market Depth
| Last trade - 15.43pm 13/09/2024 (20 minute delay) ? |
| IPD (ASX) Chart |